Hydra Biosciences has applied its leading expertise in Transient Receptor Potential (TRP) channels to discover potential new drugs for the treatment of a range of conditions, including chronic pain and disorders of the central nervous system and of the kidneys. Its program on TRPA1 antagonists for chronic pain was acquired by Eli Lilly in 2018, while two further programs on additional TRP channels are being studied in early-stage clinical trials by Boehringer Ingelheim.